Celecoxib

+ 38 more variants

• Dizziness and Headache: Some individuals may feel lightheaded or experience tension-type headaches.
• Insomnia: Difficulty falling or staying asleep has been reported in a small percentage of users.
• Pharyngitis and Rhinitis: Inflammation of the throat and nasal passages.
• Skin Rash: Mild itching or redness of the skin.
• Flatulence: Increased gas and abdominal bloating.

• Tinnitus: Ringing in the ears.
• Blurred Vision: Temporary changes in visual acuity.
• Anemia: A decrease in red blood cell count, often due to occult (hidden) GI bleeding.
• Hyperkalemia: Elevated levels of potassium in the blood, which can affect heart rhythm.

> Warning: Stop taking Celecoxib and call your doctor immediately if you experience any of the following serious symptoms:

• Cardiovascular Events: Chest pain, shortness of breath, weakness on one side of the body, or slurred speech. These may be signs of a heart attack or stroke.
• Gastrointestinal Bleeding: Black, tarry, or bloody stools; coughing up blood or vomit that looks like coffee grounds. This is a medical emergency.
• Hepatotoxicity (Liver Damage): Yellowing of the skin or eyes (jaundice), dark urine, severe fatigue, or pain in the upper right side of the stomach.
• Nephrotoxicity (Kidney Damage): Significant change in the amount of urine produced, swelling in the legs, or shortness of breath.
• Severe Skin Reactions: Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN). Watch for a painful red or purplish rash that spreads and blisters, accompanied by fever.
• Anaphylaxis: Severe allergic reaction involving swelling of the face or throat, hives, and difficulty breathing.

Prolonged use of celecoxib, especially at high doses, increases the cumulative risk of cardiovascular and renal issues. Chronic inhibition of prostaglandins in the kidneys can lead to renal papillary necrosis (death of kidney tissue) and other forms of chronic kidney disease. Long-term users should have regular blood pressure checks and lab work to monitor organ function.

The FDA has issued the highest level of warning for celecoxib, known as a Black Box Warning, regarding two major risks:

1. 1Cardiovascular Risk: NSAIDs, including celecoxib, cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction (heart attack) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Celecoxib is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
2. 2Gastrointestinal Risk: NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

Report any unusual symptoms, no matter how minor they may seem, to your healthcare provider immediately. Early detection of side effects is key to preventing long-term complications.

• Allergic Reactions / Anaphylaxis Risk: Patients with a known 'aspirin triad' (asthma, nasal polyps, and aspirin sensitivity) should not take celecoxib. Severe, life-threatening bronchial spasms can occur. Additionally, because celecoxib contains a sulfonamide moiety, patients with a history of sulfa allergies may be at higher risk for allergic reactions.
• Hepatotoxicity: Borderline elevations of liver tests may occur in up to 15% of patients. While rare, severe hepatic reactions including liver failure and jaundice have been reported. If symptoms of liver dysfunction develop, the drug must be stopped immediately.
• Hypertension (High Blood Pressure): Celecoxib can lead to the onset of new hypertension or the worsening of pre-existing high blood pressure. Blood pressure should be monitored closely during the initiation of therapy and throughout the course of treatment.
• Heart Failure and Edema: NSAIDs can cause fluid retention and edema (swelling). Celecoxib should be used with extreme caution in patients with congestive heart failure or pre-existing swelling.
• Renal Toxicity: Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury. Patients at greatest risk are those with impaired renal function, heart failure, liver dysfunction, those taking diuretics and ACE inhibitors, and the elderly.

If you are prescribed celecoxib for a chronic condition, your healthcare provider will likely require periodic monitoring, including:

• Complete Blood Count (CBC): To check for anemia, which could indicate internal bleeding.
• Liver Function Tests (LFTs): To ensure the liver is processing the medication safely.
• Renal Function Tests (BUN and Creatinine): To monitor kidney health.
• Blood Pressure: Regular checks are necessary as NSAIDs can raise blood pressure levels.

Celecoxib generally does not cause significant sedation. However, because it can cause dizziness or blurred vision in some individuals, you should observe how the medication affects you before driving or operating heavy machinery.

Consuming alcohol while taking celecoxib significantly increases the risk of gastrointestinal bleeding and stomach ulcers. It is generally advised to limit or avoid alcohol consumption during treatment.

Unlike some medications, celecoxib does not typically require a tapering schedule to avoid withdrawal. However, stopping the medication may result in a rapid return of inflammatory symptoms (pain and swelling). Always consult your doctor before discontinuing a prescribed regimen for chronic arthritis.

> Important: Discuss all your medical conditions, especially any history of heart disease, high blood pressure, or stomach ulcers, with your healthcare provider before starting Celecoxib.

• Diuretics (e.g., Furosemide, Hydrochlorothiazide): Celecoxib can reduce the natriuretic (sodium-removing) effect of diuretics, leading to fluid retention and decreased effectiveness in treating high blood pressure or edema.
• Digoxin: Some NSAIDs can increase serum digoxin levels; monitoring is advised.
• Corticosteroids: Taking celecoxib with prednisone or other steroids significantly increases the risk of developing stomach ulcers.

• High-Fat Meals: As noted in the pharmacology section, high-fat food increases the total absorption of celecoxib. While the drug can be taken with or without food, it is best to be consistent. If you take it with breakfast every day, continue to do so.
• Alcohol: Increases the risk of GI irritation and bleeding. Avoidance is strongly recommended.

• Ginkgo Biloba, Garlic, and Ginger: These supplements have mild anti-platelet effects and may increase the risk of bleeding when combined with celecoxib.
• St. John’s Wort: This herb can induce CYP enzymes, potentially reducing the effectiveness of celecoxib, though the clinical significance is less clear than with other drugs.
• Omega-3 Fatty Acids: While often taken for arthritis, high doses may increase bleeding risk when used with NSAIDs.

Celecoxib does not generally interfere with standard laboratory tests, but it may cause false-positive results in certain urine tests for other substances. It can also cause elevations in liver enzymes and BUN/creatinine, which are reflections of the drug's physiological effects rather than an interference with the test mechanism itself.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete list is essential for preventing dangerous drug-drug interactions.

Relative Contraindications

These conditions require a careful risk-benefit analysis by a physician:

• Active Peptic Ulcer Disease: Patients with active stomach or intestinal bleeding should not start celecoxib until the condition is resolved.
• Severe Heart Failure: Due to the risk of fluid retention and worsening cardiac function.
• Severe Renal Impairment: Patients with a creatinine clearance of less than 30 mL/min should generally avoid celecoxib.
• Severe Hepatic Impairment: (Child-Pugh Class C) The drug is not recommended as the liver cannot process it effectively.
• Late Pregnancy: Use is contraindicated starting at 30 weeks of gestation due to the risk of premature closure of the ductus arteriosus in the fetus.

Patients should be aware of cross-sensitivity between celecoxib and other NSAIDs. If you have had a severe reaction to ibuprofen, naproxen, diclofenac, or indomethacin, you are likely to have a similar reaction to celecoxib. Furthermore, the sulfonamide cross-reactivity is a unique consideration for this specific drug compared to other NSAIDs.

> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before prescribing Celecoxib. Do not assume that because it is a 'selective' inhibitor, it is safe for those with NSAID allergies.

Celecoxib is approved for the treatment of Juvenile Rheumatoid Arthritis (JRA) in children aged 2 to 17 years. It has not been studied in children under the age of 2 or those weighing less than 10 kg. Long-term effects on growth and development have not been specifically documented, but pediatric patients should be monitored with the same rigor as adults, particularly for renal and GI effects.

Patients over the age of 65 are at a substantially higher risk for complications from celecoxib. Of the total number of patients in clinical studies of celecoxib, a significant portion were 65 and over. While no overall differences in effectiveness were observed between these subjects and younger subjects, fatal GI events and acute renal failure are more common in the elderly. Lower starting doses and frequent monitoring are standard of care for this population.

In patients with mild to moderate renal impairment, no specific dose adjustment is typically required, but extreme caution is necessary. Celecoxib is not recommended in patients with advanced renal disease. If treatment must be initiated in a patient with kidney disease, renal function must be monitored frequently.

• Mild (Child-Pugh Class A): No dose adjustment is usually necessary.
• Moderate (Child-Pugh Class B): The daily dose should be reduced by 50%.
• Severe (Child-Pugh Class C): Use is not recommended.

> Important: Special populations require individualized medical assessment. Dosage and safety monitoring must be tailored to the specific needs of these vulnerable groups.

| Parameter | Value |

|---|---|

| Bioavailability | ~90% (relative to suspension) |

| Protein Binding | 97% |

| Half-life | 11 hours |

| Tmax | 3 hours |

| Metabolism | Hepatic (Primarily CYP2C9) |

| Excretion | Fecal 57%, Renal 27% |

• Molecular Formula: C17H14F3N3O2S
• Molecular Weight: 381.37 g/mol
• Solubility: Celecoxib is highly hydrophobic (water-fearing) and is essentially insoluble in water at physiological pH.
• Structure: It is a diaryl-substituted pyrazole. The presence of the sulfonamide group is a key structural feature that differentiates it from other NSAIDs and contributes to its COX-2 selectivity.

Celecoxib is the primary representative of the 'Coxib' class of NSAIDs. It is therapeutically categorized as an anti-rheumatic and analgesic agent. Related medications historically included rofecoxib (Vioxx) and valdecoxib (Bextra), though celecoxib is currently the only selective COX-2 inhibitor widely available in the United States and many other global markets.